MXPA04001731A - Tratamiento mejorado de cancer resistente a multiples farmacos con antagonistas de adenosina a3. - Google Patents
Tratamiento mejorado de cancer resistente a multiples farmacos con antagonistas de adenosina a3.Info
- Publication number
- MXPA04001731A MXPA04001731A MXPA04001731A MXPA04001731A MXPA04001731A MX PA04001731 A MXPA04001731 A MX PA04001731A MX PA04001731 A MXPA04001731 A MX PA04001731A MX PA04001731 A MXPA04001731 A MX PA04001731A MX PA04001731 A MXPA04001731 A MX PA04001731A
- Authority
- MX
- Mexico
- Prior art keywords
- adenosine
- antagonists
- enhancing treatment
- mdr cancer
- receptor antagonists
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invencion describe el uso de antagonistas del receptor de adenosina A3 de alta afinidad para mejorar el tratamiento quimioterapeutico de canceres que expresan los receptores de adenosina A3 y canceres que expresan P-glicoproteina o MRP. En modalidades preferidas, los antagonistas del receptor de adenosina A3 se administran antes o durante la administracion de una familia de taxano, vinca alcaloide, camptotecina o agente quimioterapeutico de antibiotico.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39100902P | 2002-06-24 | 2002-06-24 | |
US39439502P | 2002-07-08 | 2002-07-08 | |
PCT/US2003/020118 WO2004000237A2 (en) | 2002-06-24 | 2003-06-24 | Enhancing treatment of mdr cancer with adenosine a3 antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04001731A true MXPA04001731A (es) | 2004-05-31 |
Family
ID=30003180
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04001731A MXPA04001731A (es) | 2002-06-24 | 2003-06-24 | Tratamiento mejorado de cancer resistente a multiples farmacos con antagonistas de adenosina a3. |
Country Status (10)
Country | Link |
---|---|
US (2) | US20040067932A1 (es) |
EP (1) | EP1515719A4 (es) |
JP (1) | JP2005530858A (es) |
AU (1) | AU2003245693A1 (es) |
BR (1) | BR0305106A (es) |
CA (1) | CA2464539A1 (es) |
IL (1) | IL160538A0 (es) |
MX (1) | MXPA04001731A (es) |
NZ (1) | NZ531327A (es) |
WO (1) | WO2004000237A2 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1766060A4 (en) * | 2004-05-14 | 2007-11-28 | King Pharmaceuticals Res & Dev | METHODS FOR DIAGNOSIS AND PROGNOSIS OF SOLID TUMORS AND MELANOMAS |
CN101083998A (zh) * | 2004-11-22 | 2007-12-05 | 王者制药研究发展有限公司 | 用腺苷a3受体激动剂强化治疗hif-1介导的病症 |
EP2094268A2 (en) * | 2006-05-26 | 2009-09-02 | Bayer HealthCare, LLC | Drug combinations with substituted diaryl ureas for the treatment of cancer |
WO2008135232A1 (en) * | 2007-05-02 | 2008-11-13 | Riccardo Cortese | Use and compositions of purine derivatives for the treatment of proliferative disorders |
US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
US9199102B2 (en) | 2009-07-21 | 2015-12-01 | Oradin Pharmaceutical Ltd. | A3 adenosine receptor ligands for modulation of pigmentation |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5994088A (en) * | 1991-03-08 | 1999-11-30 | Board Of Trustees Of The University Of Illinois | Methods and reagents for preparing and using immunological agents specific for P-glycoprotein |
US6210917B1 (en) * | 1993-12-29 | 2001-04-03 | The Regents Of The University Of California | Method for suppressing multiple drug resistance in cancer cells |
US6066642A (en) * | 1996-01-29 | 2000-05-23 | The United States Of America As Represented By The Department Of Health And Human Services | Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists |
US6087350A (en) * | 1997-08-29 | 2000-07-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Use of pretreatment chemicals to enhance efficacy of cytotoxic agents |
US6326390B1 (en) * | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
US6921825B2 (en) * | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
US6358964B1 (en) * | 2000-07-26 | 2002-03-19 | King Pharmaceuticals Research And Development, Inc. | Adenosine, A3 receptor modulators |
-
2003
- 2003-06-24 US US10/603,406 patent/US20040067932A1/en not_active Abandoned
- 2003-06-24 EP EP03739312A patent/EP1515719A4/en not_active Withdrawn
- 2003-06-24 MX MXPA04001731A patent/MXPA04001731A/es not_active Application Discontinuation
- 2003-06-24 JP JP2004530977A patent/JP2005530858A/ja not_active Withdrawn
- 2003-06-24 AU AU2003245693A patent/AU2003245693A1/en not_active Abandoned
- 2003-06-24 NZ NZ531327A patent/NZ531327A/en unknown
- 2003-06-24 CA CA002464539A patent/CA2464539A1/en not_active Abandoned
- 2003-06-24 BR BR0305106-4A patent/BR0305106A/pt not_active IP Right Cessation
- 2003-06-24 IL IL16053803A patent/IL160538A0/xx unknown
- 2003-06-24 WO PCT/US2003/020118 patent/WO2004000237A2/en active Application Filing
-
2008
- 2008-12-18 US US12/338,631 patent/US20090203719A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU2003245693A1 (en) | 2004-01-06 |
US20040067932A1 (en) | 2004-04-08 |
WO2004000237A3 (en) | 2004-02-26 |
IL160538A0 (en) | 2004-07-25 |
US20090203719A1 (en) | 2009-08-13 |
WO2004000237A2 (en) | 2003-12-31 |
JP2005530858A (ja) | 2005-10-13 |
EP1515719A4 (en) | 2005-08-17 |
NZ531327A (en) | 2006-12-22 |
BR0305106A (pt) | 2004-09-28 |
EP1515719A2 (en) | 2005-03-23 |
CA2464539A1 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004018000A3 (en) | Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents | |
NZ547191A (en) | Treatment of proliferative diseases using an antisense IAP oligomer and chemotherapeutic agent | |
JP2018515613A (ja) | 癌を治療するための白金含有抗腫瘍剤とジアンヒドロガラクチトールの類縁体又は誘導体の組み合わせ | |
WO2004045532A3 (en) | Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis | |
NZ621972A (en) | Nanoparticle comprising rapamycin and albumin as anticancer agent | |
WO2001066123A3 (en) | Composition consisting of phy906 and chemotherapeutic agents | |
IL231810A (en) | History of itensinoid and pharmaceutical preparations containing the same methods of preparation and use thereof for cancer treatment | |
HUP0200264A3 (en) | Use of estrogen agonists/antagonists for producing pharmaceutical compositions suitable for the treatment of cancers | |
BG108072A (en) | The use of epothilone derivatives for the treatment of refractory tumors | |
WO2004000224A3 (en) | Enhancing treatment of mdr cancer with adenosine a3 antagonists | |
MXPA04001731A (es) | Tratamiento mejorado de cancer resistente a multiples farmacos con antagonistas de adenosina a3. | |
WO2004002463A3 (en) | Method of promoting smoking cessation | |
RS20050481A (en) | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents | |
ME00056B (me) | Kombinacija kombrestatina i anti-kancer agensa | |
EE200200471A (et) | Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks | |
WO2006020618A8 (en) | Compositions and methods for treating leukemia | |
GR3029666T3 (en) | Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine | |
Hartmann et al. | Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma | |
AR003421A1 (es) | Mezclas de bencimidazoles sustituidos, un proceso para su preparacion y el uso de los mismos para preparar agentes contra protozoos parasitarios | |
EP1186318A3 (en) | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | |
JP2006504721A5 (es) | ||
WO2000053148A3 (en) | Methods and compositions for treating erectile dysfunction | |
AU2003226765A8 (en) | Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents | |
EP1246619A4 (en) | UROTENSIN II RECEPTOR ANTAGONISTS | |
Hartmann | Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |